21-ID-02

Committee: Infectious Disease

Title: Revision to the Standardized Case Definition, Case Classification, and Public Health Reporting for Acute Flaccid Myelitis

☒ Check this box if this position statement is an update to an existing standardized surveillance case definition and include the most recent position statement number here: 19-ID-05 and Interim-20-ID-04.

Synopsis: This position statement updates the standardized case definition for acute flaccid myelitis.

I. Statement of the Problem

Acute flaccid myelitis (AFM) is a rare but serious paralytic illness. The causes of AFM remain largely unknown, and no laboratory test is available for case confirmation. Previous case definition revisions have added specificity to the AFM case criteria intended to allow increased understanding of the baseline incidence and epidemiology of AFM and its public health impact in the United States. The clinical case criterion is defined as a person with sudden onset of acute flaccid limb weakness. The AFM case definition, as defined in CSTE position statement 19-ID-05, is based on gray matter lesions in the spinal cord.

This position statement proposes to further improve case ascertainment and reporting consistency across jurisdictions by adding laboratory/imaging criteria for suspect cases, adding case ascertainment criteria that allow for consideration of potential AFM cases identified post-mortem, and allowing for inclusion of persons with evidence of myelitis on autopsy as AFM cases:

- The suspect case classification criteria have been modified to include supportive laboratory/imaging criteria.
- Additional criteria have been added under case ascertainment to allow for reporting of suspect AFM cases identified post-mortem.
- The confirmed case classification is revised to include persons who died and did not have an MRI performed but have evidence of myelitis on autopsy.

II. Background and Justification

Acute flaccid myelitis (AFM) is characterized by rapid onset of flaccid weakness in one or more limbs and distinct abnormalities of the spinal cord gray matter on magnetic resonance imaging (MRI). AFM is a subtype of acute flaccid paralysis (AFP), defined as acute onset of flaccid weakness absent of features suggesting an upper motor neuron disorder. The term ‘AFP’ is a generalized ‘umbrella’ term and includes multiple clinical entities, including paralytic poliomyelitis, AFM, Guillain-Barré syndrome (GBS), acute transverse myelitis, toxic neuropathy, and muscle disorders. The annual rate of AFP among children under 15 years of age is approximately 1 per 100,000 children. Although AFP surveillance is commonly conducted in many countries currently still at risk for ongoing transmission of poliovirus, AFP is not under standardized surveillance or nationally notifiable in the United States. Surveillance and assessment for AFP has not been routinely performed since polio was eradicated from the U.S.

In the summer and fall of 2014, an apparent increase in reports of AFM occurred in the U.S. Standardized surveillance was established in 2015 to monitor this illness and attempt to estimate baseline incidence (1). Data collected since standardized surveillance was established have helped to identify subsequent increases in reports nationally during 2016 and 2018 and have provided additional valuable information on the clinical presentation to help better characterize clinical features and epidemiology of cases of AFM.

From the summer/fall of 2014 through December 2020, 650 confirmed cases of AFM from 49 states and the District of Columbia were reported to the Centers for Disease Control and Prevention (CDC), with peaks...
occurring in 2014, 2016, and 2018. All confirmed patients had distinctive abnormalities of the spinal cord gray matter on MRI (2), and a majority reported a respiratory or febrile illness in the days before onset of neurologic symptoms (3, 4, CDC unpublished data). One fatality was reported in a confirmed case of AFM during the acute phase of illness in 2017.

Testing of biological specimens, including CSF, respiratory secretions, serum, and stool, has continued through 2020, without identification of a common etiology (3, 4, CDC unpublished data). Numerous viruses, including polioviruses, flaviviruses, and non-polio enteroviruses have been associated with AFM, but viral isolation from cases is not consistent or common. However, data collected since 2014 suggest that enteroviruses, specifically EV-D68, are important factors in the epidemiology of AFM. Although the CDC AFM laboratory has expanded its focus from direct pathogen detection to identification of indirect evidence for infection and possible immune correlates of disease, exploration of the relationship between EV-D68 and AFM continues (5). Testing protocols are also being developed to look for AFM biomarkers, and studies are being designed to identify possible mechanisms for AFM.

Although cases of AFM resemble polio clinically, they would not be considered paralytic poliomyelitis without meeting epidemiologic and laboratory criteria for polio (6). To date, all stool specimens from AFM patients tested at CDC have been negative for poliovirus. Without a biological marker to confirm cases of AFM, classification of cases is challenging. Therefore, as with polio (6), review of AFM case information by experts in national AFM surveillance provides consistency for classification of AFM cases.

III. Statement of the desired action(s) to be taken

CSTE recommends the following actions:

1. Implement a standardized surveillance case definition for Acute Flaccid Myelitis (AFM).
   
   A. Utilize standard sources (e.g., reporting*) for case ascertainment for AFM. Surveillance for AFM should use the recommended sources of data to the extent of coverage presented in Section V.
   
   B. Utilize standardized criteria for case ascertainment for AFM presented in Section VI and Table VI in Technical Supplement.
   
   C. Utilize standardized criteria for case classification for AFM presented in Section VII and Table VII in Technical Supplement.

*Reporting: process of a healthcare provider or other entity submitting a report (case information) of a condition under public health surveillance TO local, state, or territorial public health.

IV. Goals of Surveillance

To provide a standard case definition to help standardize surveillance for states performing surveillance for AFM. Standardized surveillance for AFM will facilitate interpretation of apparent increases in this condition, better define the etiologic agent(s) and pathogenesis, and improve the tracking of national trends of AFM.

V. Methods for Surveillance: Surveillance for Acute Flaccid Myelitis (AFM) should use the recommended sources of data and the extent of coverage listed in Table V.

The primary source of data for AFM case ascertainment is clinician reporting to public health authorities. Clinicians should report cases meeting the clinical criteria for AFM as described in Section VI. Data from clinicians can be supplemented using data from electronic medical records, hospital discharge or outpatient records, and death certificates.
Table V. Recommended sources of data and extent of coverage for ascertainment of cases of Acute Flaccid Myelitis (AFM).

<table>
<thead>
<tr>
<th>Source of data for case ascertainment</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Population-wide</td>
</tr>
<tr>
<td>Clinician reporting</td>
<td>X</td>
</tr>
<tr>
<td>Laboratory reporting</td>
<td></td>
</tr>
<tr>
<td>Reporting by other entities (e.g., hospitals, veterinarians, pharmacies, poison centers), specify: hospitals</td>
<td>X</td>
</tr>
<tr>
<td>Death certificates</td>
<td>X</td>
</tr>
<tr>
<td>Hospital discharge or outpatient records</td>
<td>X</td>
</tr>
<tr>
<td>Data from electronic medical records</td>
<td>X</td>
</tr>
<tr>
<td>Telephone survey</td>
<td></td>
</tr>
<tr>
<td>School-based survey</td>
<td></td>
</tr>
<tr>
<td>Other, specify:</td>
<td></td>
</tr>
</tbody>
</table>

VI. Criteria for case ascertainment

A. Narrative: A description of suggested criteria for case ascertainment of a specific condition.

Report any illness to public health authorities that meets the following criteria:
- A person meeting Clinical Criteria for Reporting AND Laboratory/Imaging Criteria for Reporting.
  OR
- A person meeting Vital Records Criteria for Reporting.
  OR
- A person meeting Other Criteria for Reporting.

A1. Clinical Criteria for Reporting

- A person with onset of acute flaccid* limb weakness.**

  * Low muscle tone, limp, hanging loosely, not spastic or contracted.
  ** Clinical criteria must be paired with laboratory/imaging criteria to trigger a report to public health.

A2. Laboratory/Imaging Criteria for Reporting

- A magnetic resonance image (MRI) showing a spinal cord lesion in at least some gray matter† and spanning one or more vertebral segments, AND
- Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities.**

  † Terms in the spinal cord MRI report such as “affecting gray matter,” “affecting the anterior horn or anterior horn cells,” “affecting the central cord,” “anterior myelitis,” or “poliomyelitis” would all be consistent with this terminology.
  ** Laboratory/imaging must be paired with clinical criteria to trigger a report to public health.

A3. Epidemiologic Linkage Criteria for Reporting

Not applicable

A4. Vital Records Criteria for Reporting

Any person whose death certificate lists acute flaccid myelitis as a cause of death or a condition contributing to death.

A5. Other Criteria for Reporting

- Autopsy findings that include histopathologic evidence of inflammation largely involving the anterior horn of the spinal cord spanning one or more vertebral segments, AND
- Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities.
B. Disease-specific data elements to be included in the initial report

Disease-specific data elements to be included in the initial report are listed below.

- Basic demographics
- Clinical information:
  o Date of onset
  o Limb(s) with acute onset of weakness
    ▪ Description of limb weakness: limb(s) affected; weakness symmetric or asymmetric
    ▪ Cranial nerve involvement (e.g., extraocular movement abnormalities, facial weakness)
    ▪ Reflexes and tone (flaccid* or spastic) in affected limbs
  o Hospitalization (include duration)
- Laboratory/Imaging data:
  o Date(s) of lumbar puncture(s) (LP)
  o WBC count from CSF (cells / mm³)
  o Protein level in CSF (mg/dL)
  o Date of performance of MRI (if >1 MRI performed, date of each MRI study)†
  o Description of gray matter lesion(s) (may attach MRI report)

*Low muscle tone, limp, hanging loosely, not spastic or contracted.
†Restricted to MRIs performed in the proximate period of the suspected AFM illness; excludes neuroimaging performed for illnesses unrelated (clinically or temporally) to AFM illness.

VII. Case Definition for Case Classification

A. Narrative: Description of criteria to determine how a case should be classified.

A1. Clinical Criteria

- An illness with onset of acute flaccid* weakness of one or more limbs, AND
- Absence of a clear alternative diagnosis attributable to a nationally notifiable condition**

* Low muscle tone, limp, hanging loosely, not spastic or contracted.
** Cases with a clear alternative diagnosis attributable to a nationally notifiable condition (NNC) should be reported only once using the event code for the NNC to avoid duplicate reporting.

A2. Laboratory/Imaging Criteria

Confirmatory laboratory/imaging evidence:
- MRI showing spinal cord lesion with predominant gray matter involvement† and spanning one or more vertebral segments, AND
- Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities.

Presumptive laboratory/imaging evidence:
- MRI showing spinal cord lesion where gray matter involvement† is present but predominance cannot be determined, AND
- Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities.

Supportive laboratory/imaging evidence:
- MRI showing a spinal cord lesion in at least some gray matter† and spanning one or more vertebral segments, AND
- Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities.

† Terms in the spinal cord MRI report such as “affecting gray matter,” “affecting the anterior horn or anterior horn cells,” “affecting the central cord,” “anterior myelitis,” or “poliomyelitis” would all be consistent with this terminology.

Note: The categorical labels used here to stratify laboratory/imaging evidence are intended to support the standardization of case classifications for public health surveillance. The categorical labels should not be used to interpret the utility or validity of any laboratory/imaging test methodology.
A3. Epidemiologic Linkage

Not applicable.

A4. Other Classification Criteria

- Autopsy findings that include histopathologic evidence of inflammation largely involving the anterior horn of the spinal cord spanning one or more vertebral segments, AND
- Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities, AND
- Absence of a clear alternative diagnosis attributable to a nationally notifiable condition.

**Cases with a clear alternative diagnosis attributable to a nationally notifiable condition (NNC) should be reported only once using the event code for the NNC to avoid duplicate reporting.**

A5. Case Classifications

**Confirmed:**
- Meets clinical criteria with confirmatory laboratory/imaging evidence, OR
- Meets other classification criteria.

**Probable:**
- Meets clinical criteria with presumptive laboratory/imaging evidence.

**Suspect:**
- Meets clinical criteria with supportive laboratory/imaging evidence, AND
- Available information is insufficient to classify case as probable or confirmed.

Comment: To provide consistency in case classification, review of case information and assignment of final case classification for all suspected AFM cases will be done by experts in national AFM surveillance. This is similar to the review required for final classification of paralytic polio cases (6).

B. Criteria to distinguish a new case of this disease or condition from reports or notifications which should not be enumerated as a new case for surveillance

Not applicable.

VIII. Period of Surveillance

Surveillance should be ongoing.

IX. Data sharing/release and print criteria

Notification to CDC of all persons meeting the clinical criteria for AFM is recommended.
- States will send core/generic and disease specific data elements to CDC.
- Data will be used to determine the burden of illness due to AFM and better define the etiologic agent(s) and pathogenesis of AFM.
- The frequency of reports/feedback to the states and territories will be dependent on the current epidemiologic situation in the United States. Frequency of cases and other factors will influence communications.

CSTE recommends the following case statuses* be included in the ‘case’ count released outside of the public health agency:
- [x] Confirmed
- [ ] Probable
- [ ] Suspect
- [ ] Unknown

* Which case statuses are included in the case counts constitute the “print criteria.”
Jurisdictions (e.g., States and Territories) conducting surveillance under this case definition can voluntarily submit de-identified case information to CDC, if requested and in a mutually agreed upon format.

Production of national data summaries and national data re-release for non-NNCs:
- Prior to release of national data summaries CDC should follow the CDC/ATSDR Policy on Releasing & Sharing Data, issued on April 16, 2003 and referenced in 11-SI-01 and custodians of such data should consult the CDC-CSTE Intergovernmental Data Release Guidelines Working Group report (http://www.cste2.org/webpdfs/drgwreport.pdf) which contains data release guidelines and procedures for CDC programs re-releasing state, local, or territorial-provided data.
- CDC programs have a responsibility, in collaboration with states, localities, and territories, to ensure that CDC program-specific data re-release procedures meet the needs of those responsible for protecting data in the states and territories.

**X. Revision History**

<table>
<thead>
<tr>
<th>Position Statement</th>
<th>Section of Document</th>
<th>Revision Description</th>
</tr>
</thead>
</table>
| 19-ID-05           | Statement of the Problem | ADDED additional criteria has been added under case ascertainment to allow for reporting of suspect AFM cases identified post-mortem.  
ADDED the confirmed case classification is revised to include persons who died and did not have an MRI performed but have evidence of myelitis on autopsy.  
ADDED The suspect case classification has been modified to include supportive laboratory/imaging criteria. |
| 19-ID-05           | Criteria for case ascertainment | ADDED A5. Other Criteria for Reporting Autopsy findings that include histopathologic evidence of inflammation largely involving the anterior horn of the spinal cord spanning one or more vertebral segments, AND  
Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities.  
CLARIFIED clinical criteria must be paired with laboratory/imaging criteria to trigger a report to public health.  
CLARIFIED clinical criteria absence of clear alternative diagnosis attributable to a nationally notifiable condition via footnote. |
| 19-ID-05           | Case definition for case classification  
| 19-ID-05           | Case definition for case classification  
A2. Laboratory/Imaging criteria | ADDED to Supportive laboratory/imaging evidence:  
1) MRI showing a spinal cord lesion in at least some gray matter† and spanning one or more vertebral segments  
2) Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities |
| 19-ID-05           | Case definition for case classification | ADDED A4. Other Classification criteria  
Autopsy findings that include histopathologic evidence of inflammation largely involving the anterior horn of the spinal cord spanning one or more vertebral segments, AND  
Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities, AND  
Absence of a clear alternative diagnosis attributable to a nationally notifiable condition.**

---

† MRI showing a spinal cord lesion in at least some gray matter.  
** Absence of a clear alternative diagnosis attributable to a nationally notifiable condition.
| 19-ID-05 | Case definition for case classification A5. Case Classification | ADDED to Confirmed  
Meets other classification criteria. 
ADDED to Suspect  
1) Meets clinical criteria with supportive laboratory/imaging evidence, AND  
2) Available information is insufficient to classify case as probable or confirmed. |
| 17-ID-01 | Statement of the Problem | ADDED additional clinical criteria to include any spinal cord lesion on MRI at least partially in the gray matter, and specific diagnoses that should be excluded for reporting.  
ADDED criteria to probable case classification to include persons with spinal cord lesion on MRI where gray matter predominance cannot be distinguished.  
REMOVED requirement for CSF pleocytosis for probable case classification. |
| 17-ID-01 | Goals of Surveillance | EDITED “to provide a standard case definition for states electing to perform surveillance for AFM” to “to provide a standard case definition to help standardize surveillance for states performing surveillance for AFM. Standardized surveillance for AFM will facilitate interpretation of apparent increases in this condition, better define the etiologic agent(s) and pathogenesis, and improve the tracking of national trends of AFM.” |
| 17-ID-01 | Methods for Surveillance | EDITED “surveillance for acute flaccid myelitis (AFM) should use the recommended sources of data and the extent of coverage listed in Table III” to “the primary source of data for AFM case ascertainment is clinician reporting to public health authorities. Clinicians should report cases meeting the clinical criteria for AFM as described in Section VI. Data from clinicians can be supplemented using data from electronic medical records, hospital discharge or outpatient records, and death certificates.” |
| 17-ID-01 | Criteria for case ascertainment | ADDED additional clinical criteria to include any spinal cord lesion on MRI at least partially in the gray matter and specific diagnoses that should be excluded for reporting.  
ADDED clarification of meaning of “flaccid” as footnote. |
| 17-ID-01 | Disease specific data elements to be included in the initial report | ADDED clarification of meaning of “flaccid” as footnote.  
REMOVED Radiographic evidence of spinal cord lesion largely restricted to gray matter** and spanning one or more vertebral segments (if > 1 MRI performed, radiographic details of each MRI)**  
REMOVED footnote “Spinal cord lesions may not be present on initial MRI; a negative or normal MRI performed within the first 72 hours after onset of limb weakness does not rule out AFM.” |
| 17-ID-01 | Case Definition for Case Classification | ADDED additional clinical criteria to include any spinal cord lesion on MRI at least partially in the gray matter and specific diagnoses that should be excluded for reporting.  
ADDED clarification of meaning of “flaccid” as footnote.  
ADDED criteria to confirmed case classification to include “absence of a clear alternative diagnosis”. |
| 17-ID-01 | Period of Surveillance | EDITED “Surveillance should be ongoing. Reporting should be provided as soon as all necessary data have been ascertained and collected in completed form” to “Surveillance should be ongoing.” |
| 17-ID-01 | Data Sharing/release and print criteria | EDITED “Data may be used to measure the burden of AFM” to “Notification to CDC of all persons meeting the clinical criteria for AFM is recommended.  
• States will send core/generic and disease specific data elements to CDC.  
• Data will be used to determine the burden of illness due to AFM and better define the etiologic agent(s) and pathogenesis of AFM.  
The frequency of reports/feedback to the states and territories will be dependent on the current epidemiologic situation in the United States. Frequency of cases and other factors will influence communications.” |
| 17-ID-01 | References | ADDED additional reference (McKay, et al) |
| 17-ID-01 | Appendix | ADDED appendix to include examples of additional information necessary for case classification as referenced in Sections VI.B and VII. |
XI. References


XII. Coordination

Subject Matter Expert (SME) Consultants:

PRIMARY SME

(1) Adriana Lopez, MHS
    Epidemiologist
    Centers for Disease Control and Prevention
    1600 Clifton Road, NE
    Atlanta, GA 30329
    Telephone: 404-639-8369
    Email: ail7@cdc.gov

ADDITIONAL SME(s)

(1) Janell Routh, MD, MHS
    Medical Officer
    Centers for Disease Control and Prevention
    1600 Clifton Road, NE
    Atlanta, GA 30329
    Telephone: 404-718-1153
    Email: lyp1@cdc.gov

(2) Sarah Kidd, MD, MPH
    Medical Epidemiologist
    Centers for Disease Control and Prevention
    1600 Clifton Road, NE
    Atlanta, GA 30329
    Telephone: 404-639-8314
    Email: hgk9@cdc.gov

Agencies for Response

(1) Centers for Disease Control and Prevention
    Rochelle Walensky, MD, MPH
    Director
    1600 Clifton Road, NE
    Atlanta, GA 30329
    Telephone: 404-639-7000
    Email: Aux7@cdc.gov

Agencies for Information
N/A
XIII. Author Information

Submitting and Presenting Author:

(1) Chas DeBolt RN, MPH
    Senior Epidemiologist
    Washington State Department of Health
    1610 NE 150th Street
    Shoreline, WA 98155
    Telephone: 206-418-5431
    Email: Chas.DeBolt@DOH.WA.gov

Co-Author:

(1) ☑Active Member
    Marshall Vogt, MPH
    Epidemiologist
    Virginia Department of Health
    109 Governor Street
    Richmond, Virginia 23219
    Telephone: 804-864-8076
    Email: marshall.vogt@vdh.virginia.gov
Appendix. Examples of further information necessary for case classification as referenced in Sections VI.B, and VII.

Clinical information necessary for classification of cases meeting the clinical and laboratory/imaging criteria for AFM include:

1) Complete MRI report
2) Neurology consult note
3) Images from spinal and brain MRI
## Technical Supplement

### Table VI. Table of criteria to determine whether a case should be reported to public health authorities.

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Acute Flaccid Myelitis (AFM)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>Acute flaccid* weakness of one or more limbs</td>
<td>N</td>
</tr>
<tr>
<td><strong>Laboratory/Imaging Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>A magnetic resonance image (MRI) showing spinal cord lesion in at least some gray matter† and spanning one or more vertebral segments</td>
<td>N</td>
</tr>
<tr>
<td>Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities</td>
<td>N</td>
</tr>
<tr>
<td><strong>Vital Records Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>Any person whose death certificate lists acute flaccid myelitis as a cause of death or a condition contributing to death</td>
<td>S</td>
</tr>
<tr>
<td><strong>Other Criteria for Reporting</strong></td>
<td></td>
</tr>
<tr>
<td>Autopsy findings that include histopathologic evidence of inflammation largely involving the anterior horn of the spinal cord spanning one or more vertebral segments</td>
<td>N</td>
</tr>
<tr>
<td>Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities</td>
<td>N</td>
</tr>
</tbody>
</table>

**Notes:**

- **S** = This criterion alone is SUFICIENT to report a case.
- **N** = All “N” criteria in the same column are NECESSARY to report a case.
- * Low muscle tone, limp, hanging loosely, not spastic or contracted.
- † Terms in the spinal cord MRI report such as “affecting mostly gray matter,” “affecting the anterior horn or anterior horn cells,” “affecting the central cord,” “antero myelitis,” or “poliomyelitis” would all be consistent with this.
Table VII. Classification Table: Criteria for defining a case of Acute Flaccid Myelitis (AFM).

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Suspect</th>
<th>Probable</th>
<th>Confirmed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Evidence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute flaccid* weakness of one or more limbs</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Absence of a clear alternative diagnosis attributable to a nationally notifiable condition**</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td><strong>Laboratory/Imaging Evidence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI showing spinal cord lesion with predominant gray matter involvement† and spanning one or more vertebral segments</td>
<td></td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>MRI showing spinal cord lesion where gray matter involvement† is present but predominance cannot be determined</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>MRI showing spinal cord lesion in at least some of the gray matter† and spanning one or more vertebral segments</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td><strong>Other Evidence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autopsy findings that include histopathologic evidence of inflammation largely involving the anterior horn of the spinal cord spanning one or more vertebral segments</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormalities</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Absence of a clear alternative diagnosis attributable to a nationally notifiable condition**</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insufficient information to classify case as probable or confirmed</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Criteria to distinguish a new case:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Notes:
S = This criterion alone is SUFFICIENT to classify a case.
N = All “N” criteria in the same column are NECESSARY to classify a case. A number following an “N” indicates that this criterion is only required for a specific disease/condition subtype (see below). If the absence of a criterion (i.e., criterion NOT present) is required for the case to meet the classification criteria, list the absence of criterion as a necessary component.
* Low muscle tone, limp, hanging loosely, not spastic or contracted.
** Cases with a clear alternative diagnosis attributable to a nationally notifiable condition (NNC) should be reported only once using the event code for the NNC to avoid duplicate reporting.
† Terms in the spinal cord MRI report such as “affecting mostly gray matter,” “affecting the anterior horn or anterior horn cells,” “affecting the central cord,” “anterior myelitis,” or “poliomyelitis” would all be consistent with this.